This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
MAP2K3 / Dual specificity mitogen-activated protein kinase kinase 3 · IHC design guide
Design Immunohistochemistry for MAP2K3
Plan chromogenic MAP2K3 IHC in paraffin sections using the IHC-validated antibody's documented conditions (datasheet PB9763). Compare cell-specific cytoplasmic staining with tissue references while accounting for the reported disagreement between antibody staining and RNA expression (HPA tissue IHC).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
MAP2K3 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Cytoplasmic staining in most tissues (HPA tissue IHC) | |
| Staining pattern | Cytoplasmic signal in glandular and marrow hematopoietic cells (HPA tissue IHC) | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet PB9763) | |
| Positive control | Appendix+4 more · see all | |
| Negative control | Adipose tissue+3 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across sections (standard IHC practice; not target-specific) | |
| Caveat | Antibody staining has low consistency with RNA expression (HPA tissue IHC) | |
| Regulation | Expression regulation unreported (UniProt) | |
| Isoform / epitope | 3 isoforms; epitope coverage is unspecified (UniProt) |
Section 1
Recommended MAP2K3 IHC & IF Protocols
The catalog antibody protocol uses heat-mediated EDTA retrieval (datasheet: PB9763). Two published MAP2K3 IHC protocols provide tissue-specific comparisons (PMC3852118; PMC4466407).
| Sample | Paraffin-embedded human liver cancer tissue; fixative not specified (datasheet PB9763) |
| Fixation | Image fixative and duration unreported (datasheet PB9763); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet PB9763); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet PB9763) |
| Primary antibody | Rabbit anti-MAP2K3, 2-5μg/ml (datasheet PB9763) |
| Primary incubation | Overnight at 4 °C (datasheet PB9763) |
| Detection | HRP-conjugated secondary, DAB chromogen (datasheet PB9763) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | MAP2K3-positive staining in glandular cells of appendix (HPA tissue IHC: Medium). HPA tissue profile: Cytoplasmic expression in most tissues. No signal in the no-primary control. |
💡Decision noteStart with EDTA pH 8.0 heat retrieval for the catalog antibody (datasheet: PB9763). The published protocols use pH 6.0 citrate conditions (PMC3852118; PMC4466407).
Section 2
What Is the Expected MAP2K3 Staining Pattern?
In paraffin-section IHC, expect predominantly cytoplasmic MAP2K3 staining across many tissues, including medium staining in appendix glandular cells, bone marrow hematopoietic cells and cerebral cortex neurons (HPA tissue IHC). MAP2K3 has no transmembrane segment (UniProt P46734 topology). HPA rates the tissue antibody Approved but reports low consistency between staining and RNA expression (HPA tissue IHC).
| Cytoplasmic signal in appendix glandular cells, bone marrow hematopoietic cells or cerebral cortex neurons. | This matches the reported compartment and cell types. HPA calls each example Medium, so assess staining against the local background rather than expecting intense signal throughout every section (HPA tissue IHC). |
| Signal appears exclusively at cell membranes or in extracellular material. | That distribution does not match the predominantly cytoplasmic tissue profile or the cytosol and nucleoplasm seen by ICC-IF (HPA tissue IHC; HPA ICC-IF). Check morphology, counterstain and detection controls before assigning it to MAP2K3 (general IHC practice). Nuclear signal alone needs more cautious interpretation because ICC-IF reports nucleoplasmic localization (HPA ICC-IF). |
| Strong signal is confined to adipocytes, liver cholangiocytes or smooth muscle cells. | Those cell types are listed as Not detected in the sampled HPA tissue IHC results. Consider cross-reactivity or local detection activity, while recognizing that an HPA negative observation does not prove universal absence (HPA tissue IHC; general IHC practice). |
| Brown color spreads across tissue, empty spaces or many unrelated structures. | A diffuse pattern is difficult to reconcile with the reported cell-associated cytoplasmic staining (HPA tissue IHC). Consider nonspecific binding, residual endogenous detection activity or excessive chromogen development; compare with a no-primary control and the counterstained morphology (general IHC practice). |
| No detectable signal in an otherwise intact appendix or bone marrow section. | HPA reports Medium staining in appendix glandular cells and bone marrow hematopoietic cells, making them useful comparison sites (HPA tissue IHC). First assess control performance and section quality; HPA's low staining–RNA consistency limits how strongly one negative specimen can be interpreted (HPA tissue IHC; general IHC practice). |
💡Expected MAP2K3 appearanceA credible positive result is cell-associated, chiefly cytoplasmic Medium staining in an HPA-listed positive cell type; uniform extracellular color or isolated strong staining in an HPA-listed undetected cell type warrants investigation (HPA tissue IHC).
| Tissue and cell choice | HPA reports Medium staining in eight listed examples, including bronchial respiratory epithelium, cerebellar Purkinje cells and colon endothelium; it lists adipocytes and liver cholangiocytes as Not detected (HPA tissue IHC). Select comparisons by the named cell type, since neighboring cells in the same section need not share its reported level (general IHC practice). |
| IHC evidence strength | The listed antibody, CAB018548, has Approved IHC status; the tissue profile also flags low consistency between staining and RNA expression (HPA antibodies; HPA tissue IHC). Treat the reported pattern as a comparison for interpreting slides, and use appropriate controls when a result would support a biological conclusion (general IHC practice). |
| Protein form and epitope | UniProt lists 3 isoforms, a protein kinase region at residues 64–325, no signal peptide, no propeptide and no transmembrane segment (UniProt P46734). The supplied record does not map this antibody's epitope to an isoform or domain, so it cannot predict isoform-specific staining or an epitope-specific retrieval response. |
| Activation and phosphorylation | MAP2K3 is a stress- and cytokine-responsive kinase, and UniProt lists modified residues including Ser218 and Thr222 (UniProt P46734). Those facts do not establish that this catalog antibody distinguishes activated from total MAP2K3; interpret its staining as antibody signal unless separate epitope evidence is available. |
| IF/ICC: where should signal appear? | HPA reports Approved nucleoplasm and cytosol localization, with ICC-IF images listed for A-549 and U-251MG (HPA ICC-IF). This is a compartment comparison for the separate IF/ICC guide, not an IHC protocol or a reason to require nuclear staining in every paraffin section. |
| Situation | Likely cause | Next action |
|---|---|---|
| Expected positive cells are unstained. | The run may lack usable detection, or signal may fall below visual detection; HPA reports Medium staining in the named appendix and bone marrow cells (HPA tissue IHC; general IHC practice). | Check section morphology, antibody application, detection reagents and a same-run positive control before concluding that the specimen lacks MAP2K3 (general IHC practice). |
| Most of the section is uniformly brown. | Nonspecific binding, endogenous detection activity or prolonged chromogen development can obscure cellular staining (general IHC practice). | Review the no-primary control, blocking and detection steps; shorten development or adjust antibody concentration according to the validated IHC workflow (general IHC practice). |
| Signal is concentrated on edges, folds or damaged areas. | Section artifacts can concentrate reagent or distort apparent cellular localization (general IHC practice). | Judge intact interior tissue with the counterstain; repeat on a well-mounted section if the apparent pattern depends on damaged regions (general IHC practice). |
| Staining is exclusively membranous or extracellular. | The observed distribution conflicts with the reported cytoplasmic tissue pattern and cytosol/nucleoplasm ICC-IF pattern (HPA tissue IHC; HPA ICC-IF). | Check the no-primary control and cell boundaries, then confirm any persistent unexpected pattern with an independently validated approach (general IHC practice). |
| An HPA-listed undetected cell type stains strongly. | Cross-reactivity or background is possible; HPA lists adipocytes, cholangiocytes, smooth muscle cells and vaginal squamous epithelium as Not detected in its sampled tissue results (HPA tissue IHC). | Compare the suspect cells with adjacent positive cell types and controls. Record the discrepancy without treating one HPA observation as a universal negative rule (HPA tissue IHC; general IHC practice). |
| Nuclear signal appears alongside cytoplasmic signal. | HPA ICC-IF reports both nucleoplasm and cytosol localization, while its tissue IHC summary emphasizes cytoplasmic expression (HPA ICC-IF; HPA tissue IHC). | Assess whether nuclear color follows intact nuclei and exceeds the no-primary control; document compartment-specific scoring separately if both signals remain credible (general IHC practice). |
Experiment evidence
IHC & IF images showing MAP2K3 staining
PB9763 · IHCIHC analysis of MEK3 using anti-MEK3 antibody (PB9763). MEK3 was detected in a paraffin-embedded section of human liver cancer tissue. Heat
PB9763 · IHCIHC analysis of MEK3 using anti-MEK3 antibody (PB9763). MEK3 was detected in a paraffin-embedded section of human ovarian cancer tissue. Hea
PB9763 · IFIF analysis of MEK3 using anti-MEK3 antibody (PB9763). MEK3 was detected in an immunocytochemical section of CACO-2 cells. Enzyme antigen re
M02916-1 · IHCImmunohistochemical analysis of paraffin-embedded human liver, using MEK3 Antibody.
M02916 · IFImmunofluorescent analysis of Hela cells, using MEK3/MEK6 Antibody.
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000034152-MAP2K3/tissue/cerebral+cortex#imid_4878464
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000034152-MAP2K3/tissue/colon#imid_4878398
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000034152-MAP2K3/tissue/liver#imid_4878399
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000034152-MAP2K3/tissue/kidney#imid_4878400
HPA · ICC-IF A-549Human Protein Atlas immunofluorescence, A-549, antibody CAB018548; green = MAP2K3, blue = nucleus, red = microtubules.
HPA · ICC-IF A-549Human Protein Atlas immunofluorescence, A-549, antibody CAB018548; green = MAP2K3, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for MAP2K3 IHC & IF
🧪Run appendix first and look for staining in glandular cells (HPA: Appendix glandular cells, Medium). Use adipose tissue as the negative tissue, where adipocytes are not detected (HPA: Adipose tissue adipocytes, Not detected); cells outside the glandular compartment on the appendix slide should show only background signal, without assuming they are biologically MAP2K3-negative.
Positive control tissue: Appendix (Glandular cells, HPA Medium)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show MAP2K3 in A-549, U-251MG, with annotated localisation: Nucleoplasm (approved), Cytosol (approved) (HPA subcellular).
Technical controls: Include a no-primary (secondary-only) control, a concentration-matched nonimmune rabbit IgG isotype control for the rabbit primary, and MAP2K3 knockout material or a validated peptide-block control (caption: rabbit anti-MEK3 PB9763; standard IHC practice). For chromogenic appendix sections, block endogenous peroxidase and check inflammatory cells for residual DAB signal (standard IHC practice).
⚠️Feasibility: A target-specific fixation window or fixation effect is unreported, and the selected PB9763 tissue-IHC caption does not state the fixative (selected-SKU caption: fixative not stated). The caption uses heat retrieval in EDTA at pH 8.0 on a paraffin section, but does not establish that retrieval is required for every specimen (selected-SKU caption: EDTA pH 8.0); frozen-section performance and whether IF is easier are unreported. ICC-IF images are available in A-549 and U-251MG, with nucleoplasm and cytosol listed as approved locations (HPA subcellular); for appendix IHC, assess inflammatory-cell peroxidase as a possible staining artefact (standard IHC practice).
HPA tissue IHC evidence for MAP2K3
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Approved — Low consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Appendix | Glandular cells | Medium | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | Medium | Protein (IHC) | HPA → |
| Breast | Glandular cells | Medium | Protein (IHC) | HPA → |
| Bronchus | Respiratory epithelial cells | Medium | Protein (IHC) | HPA → |
| Cerebellum | Purkinje cells | Medium | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Liver | Cholangiocytes | Not detected | Protein (IHC) | HPA → |
| Smooth muscle | Smooth muscle cells | Not detected | Protein (IHC) | HPA → |
| Vagina | Squamous epithelial cells | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced MAP2K3 IHC Tips
Troubleshoot MAP2K3 staining in paraffin sections by checking retrieval, tissue handling, cell compartment, controls and scoring before interpreting DAB signal.
What retrieval should I try first when MAP2K3 staining is weak?
Use heat mediated retrieval in EDTA at pH 8.0 for paraffin sections (datasheet PB9763). The catalog antibody detected MAP2K3 in paraffin embedded human liver cancer tissue after this retrieval, followed by 2 μg/ml primary antibody overnight at 4°C (datasheet PB9763). Because the caption gives no heating duration, record the instrument, temperature and time before adjusting retrieval intensity (datasheet PB9763; standard IHC practice). If staining remains weak, compare retrieval durations on matched sections while holding antibody concentration and DAB development constant (standard IHC practice). Check a positive control alongside each condition so tissue variation does not masquerade as a retrieval effect (standard IHC practice).
How should I troubleshoot fixation related loss of MAP2K3 staining?
Target specific fixation sensitivity is unknown: the selected paraffin tissue caption does not state a fixative (datasheet PB9763). Record fixative, fixation duration and processing history for each specimen, and compare matched tissue sections when investigating weak signal (standard IHC practice). Test retrieval adjustments on sections processed together, using the documented EDTA pH 8.0 condition as the starting point (datasheet PB9763; standard IHC practice). Include a consistently processed positive control to distinguish a batch handling problem from tissue dependent expression (standard IHC practice). Do not infer fixation tolerance from MAP2K3 phosphorylation sites or tissue staining patterns; neither supplies a fixation comparison (UniProt P46734 modified residues; HPA tissue IHC).
Where should I expect MAP2K3 staining, and when is localisation suspicious?
Assess cytoplasmic staining first: tissue IHC describes cytoplasmic expression in most tissues (HPA tissue IHC). Nucleoplasmic and cytosolic signal can also be plausible, although that compartment evidence comes from ICC/IF rather than this paraffin IHC assay (HPA subcellular). MAP2K3 has no annotated transmembrane segment, so a sharp membrane only pattern needs independent validation (UniProt P46734 topology; standard IHC practice). Compare compartment patterns within morphologically intact cells and against a no primary control, keeping counterstain and DAB development consistent (standard IHC practice). Score cell types separately because HPA reports medium signal in bone marrow hematopoietic cells and undetected signal in liver cholangiocytes (HPA tissue IHC).
Could isoforms or phosphorylation explain inconsistent MAP2K3 staining?
MAP2K3 has 3 listed isoforms, so check the antibody immunogen or mapped epitope before assuming every isoform is detected (UniProt P46734 isoforms; standard IHC practice). Its kinase domain spans residues 64–325, and listed modified residues include phosphoserines 218 and phosphothreonine 222 (UniProt P46734 domains and modified residues). These annotations alone do not establish whether fixation, retrieval or phosphorylation changes this antibody’s binding (UniProt P46734; datasheet PB9763). If treatment groups differ, process matched sections together and test a second antibody against a documented, distinct epitope where available (standard IHC practice). Report total MAP2K3 staining as protein detection, not kinase activation, unless phosphosite specificity has been independently demonstrated (UniProt P46734 function; standard IHC practice).
How can I compare MAP2K3 IHC with a multiplex IF experiment?
Treat IF/ICC as a separate assay when comparing it with this chromogenic paraffin IHC result (standard IHC/IF practice). Multiplex MAP2K3 with a marker identifying the expected cell population, such as a validated hematopoietic cell marker in bone marrow, where HPA reports medium hematopoietic staining (HPA tissue IHC; standard IF practice). Choose fluorophores after measuring tissue autofluorescence in unstained controls, and separate emission channels to limit bleed through (standard IF practice). Because MAP2K3 lacks a transmembrane segment and HPA places it in cytosol and nucleoplasm, optimise permeabilisation for intracellular epitope access (UniProt P46734 topology; HPA subcellular; standard IF practice). Do not transfer the paraffin IHC caption’s retrieval or unstated fixation conditions to IF without validation (datasheet PB9763; standard IF practice).
What should I check when DAB background obscures MAP2K3 staining?
Run a no primary control to identify signal from secondary reagent, endogenous peroxidase or DAB deposition (standard IHC practice). Block endogenous peroxidase and check washing, serum blocking and DAB development on matched sections before increasing antibody dilution (standard IHC practice). The selected caption used 10% goat serum, 2 μg/ml primary overnight at 4°C, and a peroxidase conjugated secondary for 30 minutes at 37°C (datasheet PB9763). Compare clean cellular staining with control sections rather than accepting diffuse precipitate or staining confined to section edges (standard IHC practice). Keep retrieval and development conditions recorded so a background improvement can be attributed to a specific change (standard IHC practice).
How should I quantify MAP2K3 staining across paraffin sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define the cell population and compartment before scoring; tissue IHC describes predominantly cytoplasmic expression, while ICC/IF also supports nucleoplasmic localisation (HPA tissue IHC; HPA subcellular). For chromogenic sections, use an H-score combining intensity and percentage of positive cells, or report percentage positive cells within a fixed compartment (standard IHC practice). Normalise counts to the number of eligible cells; if measuring positive cell density, report cells per mm² of viable analysed tissue (standard IHC practice). Hold retrieval, antibody exposure, imaging and DAB development constant across comparison groups (standard IHC practice). Record tissue region and cell type separately because HPA staining differs among annotated populations (HPA tissue IHC).
How do I distinguish true MAP2K3 signal from staining artefact?
A credible result follows cell boundaries and plausible compartments: HPA tissue IHC reports cytoplasmic expression, and ICC/IF supports cytosol and nucleoplasm (HPA tissue IHC; HPA subcellular). Check cell identity against morphology and controls, since HPA reports medium staining in bone marrow hematopoietic cells but no detection in liver cholangiocytes (HPA tissue IHC). Exclude section edges, folds and necrotic areas from scoring, and use a no primary control to assess endogenous enzyme signal (standard IHC practice). The catalog antibody’s paraffin liver cancer image demonstrates staining under its stated retrieval conditions, but does not establish specificity for every cell population (datasheet PB9763). Interpret group differences cautiously because HPA rates tissue IHC as Approved while reporting low consistency with RNA expression (HPA tissue IHC).
Boster reagents
Best MAP2K3 / Dual specificity mitogen-activated protein kinase kinase 3 IHC Antibodies
The catalog shows IHC data from human liver cancer tissue and human liver, plus IF data from HeLa cells (figure captions: PB9763, M02916-1, M02916).
Real IHC data
Anti-MEK3/MAP2K3 Antibody ®
Cat # PB9763
Real IHC data
Anti-MEK3 MAP2K3 Rabbit Monoclonal Antibody
Cat # M02916-1
Real IF data
Anti-MEK3/MEK6 MAP2K3 Rabbit Monoclonal Antibody
Cat # M02916
PB9763 shows IHC in paraffin-embedded human liver cancer tissue; M02916-1 shows IHC in paraffin-embedded human liver (figure captions: PB9763, M02916-1). M02916 shows IF in HeLa cells (figure caption: M02916); all three list human, mouse and rat reactivity (catalog: PB9763, M02916-1, M02916).
Which to pick: For tissue IHC, choose PB9763 if you want a documented starting workflow: its paraffin-section caption specifies EDTA retrieval at pH 8.0, 2 μg/ml primary antibody and DAB detection (PB9763 IHC figure caption). M02916-1 is a monoclonal alternative with a paraffin-section IHC image, while M02916 has an IF image in HeLa cells and lists ICC/IF; the fixative is unreported for both captions (catalog and figure captions: M02916-1, M02916). For cross-species planning, all three list human, mouse and rat reactivity, but their rendered images document human samples only (catalog and figure captions: PB9763, M02916-1, M02916).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry P46734 (MP2K3_HUMAN, Dual specificity mitogen-activated protein kinase kinase 3).
- Human Protein Atlas. MAP2K3 tissue IHC expression (reliability: Approved).
- Human Protein Atlas. MAP2K3 subcellular location (ICC-IF): Localized to the nucleoplasm and cytosol..
- Human Protein Atlas. MAP2K3 antibody validation summary (1 antibodies).
- MicroRNA-21 promotes hepatocellular carcinoma HepG2 cell proliferation through repression of mitogen-activated protein kinase-kinase 3. BMC cancer 2013 — PMC3852118.
- Exploring MAP2K3 as a prognostic biomarker and potential immunotherapy target in glioma treatment. Frontiers in neurology 2024 — PMC11210523.
- Differential Expression of ADAM23, CDKN2A (P16), MMP14 and VIM Associated with Giant Cell Tumor of Bone. Journal of Cancer 2015 — PMC4466407.
- The miR-19b-3p-MAP2K3-STAT3 feedback loop regulates cell proliferation and invasion in esophageal squamous cell carcinoma. Molecular oncology 2021 — PMC8096789.
- PubMed PMID:7839144 — UniProt-cited evidence.
- PubMed PMID:8900184 — UniProt-cited evidence.
- PubMed PMID:14702039 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for MAP2K3 (Dual specificity mitogen-activated protein kinase kinase 3). Expected localisation Cytoplasmic staining in most tissues (HPA tissue IHC). Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet PB9763). Validated IHC antibody: PB9763 at 2-5μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Appendix (Glandular cells); negative Adipose tissue. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human liver cancer tissue; fixative not specified (datasheet PB9763); 2. Fixation: Image fixative and duration unreported (datasheet PB9763); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet PB9763); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet PB9763); 8. Primary antibody: Rabbit anti-MAP2K3, 2-5μg/ml (datasheet PB9763); 9. Primary incubation: Overnight at 4 °C (datasheet PB9763). Watch for: Fixation: Keep fixation consistent across sections (standard IHC practice; not target-specific); Caveat: Antibody staining has low consistency with RNA expression (HPA tissue IHC); Isoform / epitope: 3 isoforms; epitope coverage is unspecified (UniProt); Regulation: Expression regulation unreported (UniProt). Evidence: UniProt P46734, HPA tissue IHC · Approved, HPA ICC-IF · nucleoplasm and cytosol., Datasheet PB9763, PMC3852118, PMC4466407. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/MAP2K3/immunohistochemistry-ihc-guide.